在严重的低血症腺病毒性肺炎中使用cidofovir
Aditi Gupta1, Pooja Khanna1, Arjun Parihar1
1Department of Pediatrics, Amrita Hospital, Mata Amritanandamayi Marg, Sector 88, Faridabad, Haryana, 121002, India.
Indian journal of pediatrics
|August 24, 2023
概括
在一个16个月大的男孩中,一个严重的腺病毒肺炎病例,对支持性护理没有反应,通过静脉注射cidofovir迅速改善. 这突出了cidofovir作为严重腺病毒感染的潜在治疗方法.
科学领域:
- 儿童传染病 儿童传染病
- 病毒学 病毒学
- 临界护理医学 临界护理医学
背景情况:
- 腺病毒感染可以在幼儿中引起严重的肺炎.
- 低血性肺炎需要迅速和有效的治疗干预.
研究的目的:
- 在婴儿中报告严重的腺病毒肺炎病例.
- 评估静脉注射西多福维尔在治疗严重腺病毒肺炎中的疗效.
主要方法:
- 一个16个月大的男孩患有严重的低血量肺炎的临床病例介绍.
- 通过鼻吸液确认腺病毒的诊断.
- 静脉注射cidofovir用于治疗的使用.
主要成果:
- 患者出现了类似流感的症状,并进展到严重的低血量肺炎.
- 腺病毒被确定为致病原体.
- 静脉注射cidofovir导致了快速的临床改善.
结论:
- 静脉注射cidofovir在治疗婴儿严重的腺病毒肺炎方面表现出显著的疗效.
- 奇多福维尔在儿科患者的严重,耐火性腺病毒感染中是一个有前途的治疗选择.
相关概念视频
Acute Respiratory Failure-IV
176
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
176
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
263
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
263
Pneumonia IV: Management
359
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
359
Acute Respiratory Failure-II
272
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
272
Acute Respiratory Failure-V
162
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
162
Acute Respiratory Failure-III
223
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
223


